Raymond James Has Pessimistic Outlook of TSE:MDP Q3 Earnings

Medexus Pharmaceuticals Inc. (TSE:MDP) – Research analysts at Raymond James decreased their Q3 2026 earnings per share estimates for shares of Medexus Pharmaceuticals in a research report issued on Tuesday, January 7th. Raymond James analyst M. Freeman now expects that the company will earn $0.22 per share for the quarter, down from their previous estimate of $0.24. Raymond James has a “Strong-Buy” rating and a $4.00 price objective on the stock. The consensus estimate for Medexus Pharmaceuticals’ current full-year earnings is $0.16 per share. Raymond James also issued estimates for Medexus Pharmaceuticals’ Q4 2026 earnings at $0.23 EPS, FY2026 earnings at $0.89 EPS, FY2027 earnings at $0.88 EPS, FY2028 earnings at $0.80 EPS and FY2029 earnings at $0.77 EPS.

A number of other research analysts also recently weighed in on the company. Alliance Global Partners raised Medexus Pharmaceuticals to a “strong-buy” rating in a research note on Monday, December 23rd. Leede Financial set a C$8.25 price target on Medexus Pharmaceuticals and gave the company a “speculative buy” rating in a research note on Monday, September 30th. Two analysts have rated the stock with a buy rating and four have issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Strong Buy” and a consensus target price of C$5.25.

Medexus Pharmaceuticals Stock Up 4.0 %

MDP stock opened at C$3.60 on Thursday. The business’s fifty day moving average is C$2.72 and its 200-day moving average is C$2.50. The company has a market cap of C$88.31 million, a P/E ratio of 72.00 and a beta of 1.96. Medexus Pharmaceuticals has a twelve month low of C$1.47 and a twelve month high of C$3.60.

About Medexus Pharmaceuticals

Medexus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada and the United States. The company focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Its primary products are IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, a prescription allergy medication; and Gleolan, an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery.